Tatsuo Higuchi

Profile
Tenure
Jun 2000 – Jan 2025
Years in office
24.6 years
Name in Japanese
樋口達夫
Title at appointment
Representative Director, President
Performance in office
Otsuka Holdings
Performance in office
FY1999FY2024Change
Revenue¥345.5billion¥2.3trillion+574%
Net margin—14.7%—
Akihiko OtsukaHiguchiInoue
Revenue¥683.8 billionRevenue¥1.4 trillionRevenue¥2.5 trillionNet margin5.4%Net margin5.8%Net margin14.7%1995/122000/122005/122010/122015/122020/122025/122030/12
Revenue¥683.8 billionRevenue¥1.4 trillionRevenue¥2.5 trillionNet margin5.4%Net margin5.8%Net margin14.7%1995/122000/122005/122010/122015/122020/122025/122030/12
Tenure

Tenure

Background

He joined Otsuka Pharmaceutical in March 1977. He became Senior Managing Director in June 1998 and Director and Executive Vice President that November, reaching the vice presidency 21 years after joining. In June 2000 he became Representative Director and President of Otsuka Pharmaceutical, and with the creation of the holding company in July 2008 he also became Representative Director, President and CEO of Otsuka Holdings. Even after moving to Representative Director and Chairman of Otsuka Pharmaceutical in March 2020, he remained President and CEO of the holding company until January 2025.

Selection

In June 2000 he became President of Otsuka Pharmaceutical, succeeding Akihiko Otsuka. The change came one year and seven months after he became Director and Executive Vice President, and 23 years after he joined. In the fiscal year before he took office, ended March 2000, non-consolidated revenue was ¥351.5 billion, roughly flat from ¥346.0 billion in FY ended March 1998. When the holding company Otsuka Holdings was launched in July 2008, Higuchi became its President and CEO as well.

Initiatives

In December 2010 the holding company Otsuka Holdings listed on the First Section of the Tokyo Stock Exchange, with a public offering and secondary sale of about ¥220 billion. After the holding company's launch, consolidated revenue grew from ¥1,084.2 billion in the fiscal year ended March 2010 to ¥2,329.8 billion in the fiscal year ended December 2024. Employees increased from 24,589 in FY ended March 2010 to 34,388 in FY ended December 2023. In the 15 years since the move to a holding company structure, consolidated revenue more than doubled.

Career

Career

Otsuka Pharmaceutical

Date Position
Mar 1977 Joined
Jun 1998 Senior Managing Director
Nov 1998 Executive Vice President
Jun 2000 Representative Director, President
Feb 2015 Representative Director, President
Mar 2020 Representative Director, Chairman
Jan 2025 Stepped down as President

Otsuka Holdings

Date Position
Jul 2008 Representative Director, President and CEO
Jan 2025 Director, Senior Advisor
References 1

References (Japanese primary sources)

  • 大塚ホールディングス 有価証券報告書【役員の状況】